Public Company Information:
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that CEO Paul C. Grint, M.D., will moderate a panel titled, “Advances Against Rare and Resistant Pathogens” at the Anti-Infectives Rx Conference to be held on September 19, 2017 at the Harvard Medical School in Boston.
The Anti-Infectives Rx Conference is a networking forum featuring discussion panels from industry CEOs, life science leaders, key academics and investors. This conference focuses on issues facing the development of anti-infective therapies, and will discuss regulatory issues, sustainability, partnering, as well as the new wave of anti-infectives.
Bacteriophages, or more simply “phages,” are the natural predators of bacteria and are thought to be the most abundant life form on earth. Phages have evolved an incredible diversity of strains that typically prey upon just a few closely related strains or species of bacteria, enabling phage therapies to precisely target pathogenic bacteria while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they are antibiotic-resistant or not, and even when they have formed protective biofilms.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.
At the Company:
Matthew Dansey, 858-800-4869
Robert H. Uhl, 858-356-5932
Russo Partners, LLC
David Schull or Maggie Beller, 212-845-4271